JM, S., JL, G. L., JJ, G., AI, C., JG, P., PS, R., . . . AC, M. (2005). A phase II trial of gemcitabine and weekly high-dose 5-fluorouracil in a 48-hour continuous-infusion schedule in patients with advanced pancreatic carcinoma. A study of the Spanish Cooperative Group for Gastrointestinal Tumour Therapy (TTD). Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 7(11), 493. https://doi.org/10.1007/BF02717002
Chicago Style (17th ed.) CitationJM, Santasusana, et al. "A Phase II Trial of Gemcitabine and Weekly High-dose 5-fluorouracil in a 48-hour Continuous-infusion Schedule in Patients with Advanced Pancreatic Carcinoma. A Study of the Spanish Cooperative Group for Gastrointestinal Tumour Therapy (TTD)." Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 7, no. 11 (2005): 493. https://doi.org/10.1007/BF02717002.
MLA (9th ed.) CitationJM, Santasusana, et al. "A Phase II Trial of Gemcitabine and Weekly High-dose 5-fluorouracil in a 48-hour Continuous-infusion Schedule in Patients with Advanced Pancreatic Carcinoma. A Study of the Spanish Cooperative Group for Gastrointestinal Tumour Therapy (TTD)." Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, vol. 7, no. 11, 2005, p. 493, https://doi.org/10.1007/BF02717002.
